Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sapropterin - Asubio Pharma/BioMarin Pharmaceutical

Drug Profile

Sapropterin - Asubio Pharma/BioMarin Pharmaceutical

Alternative Names: 6R-BH4; BH4; Biopten; Dapropterin; Dapropterin dihydrochloride; Kuvan; Phenoptin; Sapropterin dihydrochloride; SUN-0588; SUN0588r; Tetrahydrobiopterin; Tetrahydrobiopterin dihydrochloride

Latest Information Update: 15 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asubio Pharma; Daiichi Sankyo Company
  • Developer Asubio Pharma; BioMarin Pharmaceutical; Daiichi Sankyo Company; John Hopkins University
  • Class Anxiolytics; Nootropics; Pterins; Small molecules
  • Mechanism of Action Nitric oxide synthase stimulants; Phenylalanine hydroxylase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Phenylketonuria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Phenylketonuria
  • Phase II Isolated systolic hypertension
  • Discontinued Coronary disorders; Hypertension; Kidney disorders; Peripheral arterial disorders; Pulmonary hypertension; Sickle cell anaemia; Vascular disorders

Most Recent Events

  • 01 Dec 2018 BioMarin Pharmaceutical completes the phase II RIDD-HF trial for Hypertension (in heart failure patients) in USA (PO) (NCT02353312)
  • 24 Jun 2018 Biomarkers information updated
  • 19 Sep 2017 Sapropterin receives Orphan Drug status for Phenylketonuria in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top